Sanofi

Think you’re an expert on #RareDisease? Sanofi's Burcu Eryilmaz, Head of Rare Diseases, is on a myth-busting mission this #RareDiseaseDay to raise awareness about rare diseases and help drive equity. Learn more: http://spkl.io/6046AQ77M #RareDiseaseAwareness

The European Medicines Agency CHMP has recommended the approval of our treatment for chronic spontaneous urticaria (CSU) in certain children aged 2 to 11 years. If approved, it would become the first targeted treatment in the EU indicated for children in this age group with inadequately controlled CSU. Learn more: https://lnkd.in/eCJYCz_A   CC: Regeneron

Together with Drugs for Neglected Diseases initiative (DNDi) and Foundation S, we’re proud to receive a positive CHMP (Committee for Medicinal Products for Human Use) opinion from the European Medicines Agency for our new treatment for adults and adolescents with early and advanced stage gambiense sleeping sickness. This recommendation paves the way to bring innovative treatment to people affected by this deadly disease and aligns with the World Health Organization’s goal of eliminating gambiense sleeping sickness by 2030. We remain committed to advancing scientific innovation to address unmet patient needs, particularly vulnerable communities. Read our press release ➡️ http://spkl.io/6042Aau34 #ActForPatients #FoundationS #DNDi #GlobalHealth #SleepingSickness

Sanofi’s 2025 Environmental Impact Results 🌍 Sustainability isn’t an afterthought at Sanofi, it’s embedded from the very beginning. With up top 80% of a product’s environmental impact determined during development, we’re designing for a healthier planet from day one. Our 2025 achievements: • –49% GHG emissions (Scopes 1 & 2) and –14% (Scope 3) vs. 2019 • 86% renewable electricity • 89% of wasted reused, recycle, or recovered • –29% net freshwater withdrawals Eco-design is now standard for all new medicines and vaccines, as 50% of our 20 top-selling products follow eco-design principles. We’re proud to have led the Pharma Life Cycle Assessment Consortium to create PAS 2090:2025, the world’s first global standard for measuring pharmaceutical environmental impact. From recycling injection pens in Denmark and France to setting global standards, these actions turn commitments into real-world impact for patients 💜 These efforts are being recognized: • #1 most sustainable pharmaceutical company by TIME magazine (2025) • CDP A List, top 4% of companies worldwide for climate transparency and action From R&D labs to manufacturing facilities, sustainability guides every decision. Because when we design for the planet, we design for patients. The journey continues, guided by science, collaboration, and sustainability at every step. Discover our full results: http://spkl.io/6049AvIJS #Sustainability #WeNeverSettle #ClimateAction #Ecodesign

Rare diseases impact more people than you can imagine worldwide 🌍. Many have unseen symptoms and struggle to receive a diagnosis even after many years. Our team is committed to improving care for patients and families affected by #RareDiseases. Our focus spans the spectrum from accelerating early diagnosis to advancing research and development, to collaborating with the community. We believe no patient should be left waiting for answers. Hear directly from our own rare disease leaders – Karin Knobe, MD, PhD, Burcu Eryilmaz, Alaa Hamed, MD, MPH, MBA, Jeff Schaffnit and Duane Clark – as they share more about our drive for equity this #RareDiseaseDay. Learn more: http://spkl.io/6048AvIKp

Our medicine has been approved by the FDA as the first and only treatment for allergic fungal rhinosinusitis (AFRS) in certain adults and children aged 6 years and older. Learn more: https://lnkd.in/e5eHMx5U CC: Regeneron

How do we make smarter, faster decisions about our R&D pipeline? The answer includes our AI agent named "Plai". It sits in every governance meeting as an objective, data-driven voice, analyzing over a billion data points to help predict costs, timelines, and success rates of pipeline assets. Our 4-part series on AI concludes with a look at our most strategic conversations. Helen Merianos explains how this new “colleague” at the table is transforming our decision-making, helping to ensure our most innovative science becomes a potential new medicine for patients. Read here: http://spkl.io/6049AvSBv #AIPowered #WeNeverSettle

In July 2026, Paris will beat to the rhythm of inclusion, health, and sport 💜 The French capital city will host the Special Olympics Unified Football World Cup, a global celebration where athletes with and without intellectual disabilities will compete side by side, and show the world what the power of diversity truly looks like. Last week, inside the iconic Hôtel de Ville de Paris, the men’s and women’s teams for the 2026 edition were officially unveiled. A powerful moment. A reminder that sport is more than competition, it’s a platform for dignity, equality, and connection. As the event’s Official Health Partner, we are proud to reaffirm our commitment to health equity and access to care, so that everyone has the opportunity to thrive, on the field and in life. And we will bring the energy and passion of Sanofi’s volunteers to make it happen. See you in Paris this summer! 🌞 #SpecialOlympics #Health #Inclusion 

Global policies are changing faster than ever, creating a pivotal moment for the life sciences sector. The OECD-OCDE plays a key role in shaping the standards and evidence that will guide how countries innovate and compete.     At Sanofi, we believe that strong life sciences ecosystems — from R&D and clinical trials to manufacturing and supply chains — are essential for economic growth and delivering for patients.     Last week, we joined high-level discussions at the OECD, including meeting with OECD Secretary General Mathias Cormann. We asked the OECD to:     - Develop evidence demonstrating the massive return of investment that life sciences bring to member states - Create a Life Sciences Competitiveness Index, that allows for standardized benchmarking enabling countries to compare, compete, and excel globally  - Champion regulatory agility that accelerates patient access to innovation  - Formally prioritize life sciences as a strategic sector, with clear alignment across relevant ministries Through Business at OECD, Sanofi remains committed to shaping policies that strengthen competitiveness and help countries lead in innovation — while improving outcomes for patients everywhere. Hanni Rosenbaum Laura Gutierrez David Elvira, PhD Winona Rei Bolislis

What does it take to move from intention to impact and build a truly barrier-free workplace? Over four years, Raj Verma and Caroline Casey have championed Sanofi’s accessibility transformation, proving that inclusion isn’t about “special accommodations” it’s about designing for everyone, from the start. In this powerful conversation, they reveal how leadership commitment drives measurable change, why accessibility unlocks potential for all employees, and share practical strategies for building environments where everyone can thrive. This isn’t just about compliance. It’s about belonging, innovation, and unlocking the full potential of our people. Episode 1 of “Workplace Without Barriers: Building a Culture of Belonging” is live now. Listen, learn, and join the conversation on how we’re chasing the miracles of science, together, without barriers. Watch the full episode and explore the conversation here 👉 http://spkl.io/6047AQJZh #SanofiFeeling #SanofiStories